| Results of Meeting | Nov 18, 2026 | Meeting outcome | ASX |
|---|
| CEO Presentation | Nov 18, 2026 | Other filings | ASX |
|---|
| Chair's Address to Shareholders | Nov 18, 2026 | Other filings | ASX |
|---|
| Syntara Pauses SNT-9465 Phase 1b Recruitment | Nov 9, 2026 | Operations update | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 19, 2026 | Meeting notice | ASX |
|---|
| Investor Presentation Canaccord Drug & Device Conference | Oct 12, 2026 | Other filings | ASX |
|---|
| Further significant results from SNT-4728 iRBD Phase 2 trial | Oct 6, 2026 | Other filings | ASX |
|---|
| Notification regarding unquoted securities - SNT | Oct 4, 2026 | Other filings | ASX |
|---|
| Notification regarding unquoted securities - SNT | Oct 4, 2026 | Other filings | ASX |
|---|
| Syntara expands SNT-9465 skin scarring study | Sep 30, 2026 | Operations update | ASX |
|---|
| Syntara receives A$4.7m R&D Tax Incentive | Sep 20, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - SNT | Sep 14, 2026 | Financing | ASX |
|---|
| Notification of 2026 AGM Date | Sep 14, 2026 | Meeting notice | ASX |
|---|
| Appendix 4E and Annual Report | Aug 27, 2026 | Annual report | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Aug 27, 2026 | Other filings | ASX |
|---|
| Investor Update Webinar Presentation | Jul 27, 2026 | Other filings | ASX |
|---|
| Encouraging SNT-4728 Phase 2 iRBD results | Jul 5, 2026 | Other filings | ASX |
|---|
| Results of Share Purchase Plan | Jun 10, 2026 | Results | ASX |
|---|
| Share Purchase Plan Offer Booklet | May 13, 2026 | Financing | ASX |
|---|
| $8m placement and share purchase plan | Apr 29, 2026 | Financing | ASX |
|---|
| Continuation of trading halt | Apr 28, 2026 | Trading halt or suspension | ASX |
|---|
| Positive FDA feedback for Amsulostat P2b trial | Apr 27, 2026 | Operations update | ASX |
|---|
| Half Year Report and Appendix 4D | Feb 25, 2026 | Interim report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 28, 2026 | Quarterly report | ASX |
|---|
| Amsulostat and Garvan in MRFF funded pancreatic trial | Jan 20, 2026 | Operations update | ASX |
|---|
| SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited | Jan 7, 2026 | Operations update | ASX |
|---|
| Skin scarring program to progress on positive Phase1a result | Nov 25, 2025 | Other filings | ASX |
|---|
| Quarterly Shareholder Report and Appendix 4C | Oct 27, 2025 | Quarterly report | ASX |
|---|
| Positive top-line Phase 2a data confirms competitive profile | Sep 29, 2025 | Results | ASX |
|---|
| Preliminary Final Report | Aug 28, 2025 | Annual report | ASX |
|---|
| Guidance from FDA on amsulostat clinical progression | Aug 11, 2025 | Guidance | ASX |
|---|
| Reinstatement to Quotation | Aug 4, 2025 | Trading halt or suspension | ASX |
|---|
| Suspension from Quotation | Jul 31, 2025 | Trading halt or suspension | ASX |
|---|
| Quarterly Appendix 4C Cash Flow Report | Jul 31, 2025 | Quarterly report | ASX |
|---|
| Quarterly Shareholder Report | Jul 30, 2025 | Quarterly report | ASX |
|---|
| New positive interim data in Phase 2 study of SNT-5505 | Jun 12, 2025 | Other filings | ASX |
|---|
| SNT-5505 awarded US FDA Fast Track designation | Jun 9, 2025 | Operations update | ASX |
|---|
| Quarterly Activities Report | Apr 29, 2025 | Quarterly report | ASX |
|---|
| Acceleration of skin scarring program | Mar 17, 2025 | Other filings | ASX |
|---|
| Equity Raising Presentation | Dec 11, 2024 | Other filings | ASX |
|---|
| Placement | Dec 11, 2024 | Financing | ASX |
|---|
| Interim data in Phase 2 study of SNT-5505 in myelofibrosis | Dec 10, 2024 | Operations update | ASX |
|---|
| Presentation: Phase 2 study of SNT-5505 in myelofibrosis | Dec 10, 2024 | Other filings | ASX |
|---|
| Trading Halt | Dec 9, 2024 | Trading halt or suspension | ASX |
|---|
| Response to ASX Price Query | Dec 4, 2024 | Explanation request | ASX |
|---|
| Pause in Trading | Dec 3, 2024 | Trading halt or suspension | ASX |
|---|
| Appendix 4E and Annual Report to shareholders | Aug 30, 2024 | Annual report | ASX |
|---|
| Half Yearly Report and Accounts | Feb 29, 2024 | Interim report | ASX |
|---|
| PXS Company Restructure Sale of Mannitol Business | Oct 2, 2023 | Other filings | ASX |
|---|
| PXS to Receive Prepayment of 2023 Research Tax Incentive | Aug 7, 2023 | Other filings | ASX |
|---|
| Final Set of Interim Data from PXS-5505 in Myelofibrosis | Jul 12, 2023 | Other filings | ASX |
|---|
| PXS Announces Encouraging Results from Phase 1c Scar Study | May 23, 2023 | Other filings | ASX |
|---|
| After FDA Review PXS Accelerates Plans for Combination Study | Apr 11, 2023 | Other filings | ASX |
|---|
| PXS announces positive interim data from myelofibrosis trial | Oct 18, 2022 | Other filings | ASX |
|---|
| Investor Presentation | Oct 18, 2022 | Other filings | ASX |
|---|
| PXS Releases Promising Interim Data from Skin Scarring Study | Sep 25, 2022 | Other filings | ASX |
|---|
| PXS to Receive Stg2.9m from Parkinsons UK for New Trial | Aug 31, 2022 | Other filings | ASX |
|---|
| Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology | Aug 4, 2022 | Acquisition or disposal | ASX |
|---|
| Clarification Announcement | May 13, 2022 | Other filings | ASX |
|---|
| Appendix 4C Quarterly Cash Flow Report | Apr 28, 2022 | Quarterly report | ASX |
|---|
| Response to ASX Aware Query | Jan 10, 2022 | Explanation request | ASX |
|---|
| PXS Collaborators Receive Government Grants of $1.4m | Jan 5, 2022 | Other filings | ASX |
|---|
| Share Purchase Plan | Dec 20, 2021 | Financing | ASX |
|---|
| Security Purchase Plan | Nov 24, 2021 | Other filings | ASX |
|---|
| FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study | Nov 8, 2021 | Other filings | ASX |
|---|
| Appendix 4C Cash Flow Report | Oct 27, 2021 | Quarterly report | ASX |
|---|
| PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial | Oct 13, 2021 | Other filings | ASX |
|---|
| PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial | Oct 4, 2021 | Other filings | ASX |
|---|
| Pharmaxis Treatment to Prevent Wound and Burns Scars Clears | Aug 30, 2021 | Other filings | ASX |
|---|
| PXS Grants Exclusive Option to Develop High Payload Inhaler | Aug 16, 2021 | Other filings | ASX |
|---|
| PXS Drug Decreases Tumour Burden in Liver Cancer Model | Aug 4, 2021 | Other filings | ASX |
|---|
| PXS Sells Australian Distribution Rights for A$2m | Jun 30, 2021 | Other filings | ASX |
|---|
| PXS Announces First Results in Bone Marrow Cancer Trial | Jun 29, 2021 | Other filings | ASX |
|---|
| Quarterly Activity Report | Apr 30, 2021 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 30, 2021 | Quarterly report | ASX |
|---|
| Sale of Russian Distribution Rights | Apr 13, 2021 | Other filings | ASX |
|---|
| First Patient Enrolled - Clinical Trial for Cancer Treatment | Feb 21, 2021 | Other filings | ASX |
|---|
| Pharmaxis Exports CF Drug to US - US$3 Million Milestone | Feb 8, 2021 | Other filings | ASX |
|---|
| Quarterly Activity Report - December 2020 | Jan 28, 2021 | Other filings | ASX |
|---|
| Pharmaxis Receives US$7m milestone from Chiesi | Dec 29, 2020 | Other filings | ASX |
|---|
| Pharmaxis Prioritises Clinical Program on Myelofibrosis | Nov 1, 2020 | Other filings | ASX |
|---|
| September Quarter 2020 Activity Report | Oct 29, 2020 | Other filings | ASX |
|---|
| Boehringer Ingelheim discontinues development of BI 1467335 | Sep 6, 2020 | Other filings | ASX |
|---|
| Pharmaxis Awarded $1M Australian Government Grant | Sep 2, 2020 | Other filings | ASX |
|---|
| FDA Gives Green Light to Start Myelofibrosis Phase 2 Study | Aug 19, 2020 | Other filings | ASX |
|---|
| US$7 million Bronchitol Launch Milestone Brought Forward | Aug 4, 2020 | Other filings | ASX |
|---|
| Fourth Quarter Activity Report | Jul 30, 2020 | Other filings | ASX |
|---|
| Pharmaxis Quarterly Shareholder Update - March 2020 | Apr 29, 2020 | Other filings | ASX |
|---|
| PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020 | Apr 27, 2020 | Other filings | ASX |
|---|
| Quarterly Shareholder Update - December 2019 | Jan 30, 2020 | Other filings | ASX |
|---|
| Pharmaxis Business Plan Update | Dec 17, 2019 | Other filings | ASX |
|---|
| Quarterly Shareholder Update - September 2019 | Oct 30, 2019 | Other filings | ASX |
|---|
| FDA Provides Guidance on Bronchitol Approval Steps | Oct 27, 2019 | Guidance | ASX |
|---|
| Pharmaxis Receives $6.2m R&D Tax Incentive | Oct 16, 2019 | Other filings | ASX |
|---|
| Quarterly Shareholder Update - June 2019 | Jul 25, 2019 | Other filings | ASX |
|---|
| Pathway to US Bronchitol Approval Clarified in FDA Response | Jun 19, 2019 | Other filings | ASX |
|---|
| US Advisory Committee Positive Recommendation on Bronchitol | May 8, 2019 | Other filings | ASX |
|---|
| Quarterly Shareholder Update - March 2019 | Apr 29, 2019 | Other filings | ASX |
|---|
| Pharmaxis Commences Phase 1 LOX Clinical Trial | Feb 21, 2019 | Other filings | ASX |
|---|
| Quarterly Shareholder Update - December 2018 | Jan 29, 2019 | Other filings | ASX |
|---|
| Pharmaxis Announces LOXL2 Program Phase 2 Ready | Jan 16, 2019 | Other filings | ASX |
|---|
| PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA | Dec 19, 2018 | Other filings | ASX |
|---|
| Pharmaxis Announces First Relaunch Sales of Aridol in USA | Dec 12, 2018 | Other filings | ASX |
|---|
| Pharmaxis AGM - CEO Presentation | Nov 22, 2018 | Other filings | ASX |
|---|
| LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready | Nov 19, 2018 | Other filings | ASX |
|---|
| Pharmaxis Releases Positive Results of Phase 1 Clinical Tria | Nov 14, 2018 | Other filings | ASX |
|---|
| Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor | Oct 10, 2018 | Other filings | ASX |
|---|
| FDA Factory Approval and Relaunch of Aridol in US Market | Aug 14, 2018 | Other filings | ASX |
|---|
| Capital Raising Presentation | Aug 6, 2018 | Financing | ASX |
|---|
| Trading Halt Announcement - System Upgrade | Aug 5, 2018 | Trading halt or suspension | ASX |
|---|
| Quarterly Shareholder Update - June 2018 | Jul 26, 2018 | Other filings | ASX |
|---|
| LOXL2 Program Attracts Strong Partner Interest at BIO18 | Jun 13, 2018 | Other filings | ASX |
|---|
| Quarterly Shareholder Update - March 2018 | Apr 30, 2018 | Other filings | ASX |
|---|
| Pharmaxis Earns A$15 Million Milestone Payment | Jan 10, 2018 | Other filings | ASX |
|---|
| New Australian PBS Listing for Brocnhitol | Jan 1, 2018 | Other filings | ASX |
|---|
| Pharmaxis Acquires Control, Increases Stake in LOXL2 Program | Dec 13, 2017 | Acquisition or disposal | ASX |
|---|
| Boehringer Initiating Phase 2a Study Diabetic Retinopathy | Sep 7, 2017 | Other filings | ASX |
|---|
| Antifibrotic LOXL2 Program Clears Preclinical Development | Sep 5, 2017 | Other filings | ASX |
|---|
| Boehringer Ingelheim Initiates Phase IIa Study in NASH | Aug 24, 2017 | Other filings | ASX |
|---|
| Positive Recommendation for Broader Bronchitol Access in Aus | Aug 18, 2017 | Other filings | ASX |
|---|
| Preliminary Final Report June 2017 | Aug 10, 2017 | Results | ASX |
|---|
| Appendix 4C - quarterly June 2017 | Jul 28, 2017 | Quarterly report | ASX |
|---|
| Pharmaxis Announces Results of Pivotal CF Clinical Trial | Jun 12, 2017 | Other filings | ASX |
|---|
| Pharmaxis Set to Generate Further Euro 10m Milestone Payment | May 14, 2017 | Other filings | ASX |
|---|
| Pharmaxis Appoints Chiesi as Bronchitol Distributor in Italy | May 8, 2017 | Other filings | ASX |
|---|
| Appendix 4C - quarterly cash flow | Apr 18, 2017 | Quarterly report | ASX |
|---|
| Quarterly Shareholder Update March 2017 | Apr 17, 2017 | Other filings | ASX |
|---|
| Synairgen Collaboration Progress | Mar 12, 2017 | Other filings | ASX |
|---|
| Chairmans Address to Shareholders | Nov 29, 2016 | Other filings | ASX |
|---|
| Research Collaboration with Woolcock Institute | Nov 15, 2016 | Other filings | ASX |
|---|
| S&P DJ Indicies Announces March Quarterly Rebalance | Nov 7, 2016 | Other filings | ASX |
|---|
| Pharmaxis Announces Russian Approval for Bronchitol | Sep 26, 2016 | Other filings | ASX |
|---|
| Pharmaxis Completes Recruitment of CF Clinical Trial for US | Jul 14, 2016 | Other filings | ASX |
|---|
| Appendix 4C - quarterly March 2016 | Apr 14, 2016 | Quarterly report | ASX |
|---|
| US FDA Accepts Bronchitol New Drug Application for Review | Mar 30, 2016 | Other filings | ASX |
|---|
| Quarterly Share Update - December 2015 | Feb 11, 2016 | Other filings | ASX |
|---|
| Bronchitol Paediatric CF Trial Reports Postive Results | Feb 10, 2016 | Other filings | ASX |
|---|